Desmoplastic melanoma (DM) is a rare variant of melanoma with distinct clinical, histopathologic, and immunohistochemical features. Clinically, DM differs from conventional melanoma by a higher propensity for local recurrence and less frequent metastatic spread to regional lymph nodes. In its pure form, DM has a distinct appearance displaying a low density of fusiform melanocytes in a collagen-rich matrix. Whereas a number of mutations have been identified in primary melanoma, including BRAF, NRAS, GNAQ, GNA11, and KIT, and the occurrence of these mutations has been found to correlate to some extent with the histopathologic features, anatomic site, and/or mode of sun exposure, no distinct set of mutations has so far been reported for DM. To study the potential association of neurofibromin (NF1) mutations with DM, we examined 15 desmoplastic and 20 non-DMs by next-generation sequencing. Mutations of the NF1 gene were found in 14 of 15 (93%) DMs and 4 of 20 (20%) non-DMs. The high frequency of NF1 mutations in DMs suggests an important role for NF1 in the biology of this type of melanoma.
D esmoplastic melanoma (DM) is a rare variant of primary melanoma with distinct clinical, histopathologic, and immunohistochemical features. [1] [2] [3] [4] It tends to affect the head and neck region of elderly individuals 1,3 but may occur anywhere, even in the young. 5 In its clinical course DM differs from other melanomas by a higher propensity for persistent growth/local recurrence. 4, 6 DM only rarely metastasizes to regional lymph nodes. 7 DM has been classified into pure and mixed variants. [8] [9] [10] [11] Among patients with thick tumors, those with pure DM have a more favorable prognosis. [8] [9] [10] Histopathologically, the tumor cells of DM are usually fusiform and amelanotic. In its pure form, the tumor cells are dispersed at a low cell density in a densely collagenous matrix. Immunohistochemically, the tumor cells of DM often fail to react with antibodies to melan-A/MART-1, microphthalmia-associated transcription factor, tyrosinase, or gp100 12 but are usually positive for S100 protein, nerve growth factor receptor, and/or SOX10. [12] [13] [14] [15] Little is known about genetic changes in DM. Whereas a number of mutations have been identified in melanoma, in particular mutations in BRAF (codon V600), NRAS, GNAQ, GNA11, and KIT, they are usually absent in DM. In a recent next-generation sequence analysis of a DM with sarcomatoid dedifferentiation, we found inactivating mutations of neurofibromin 1 (NF1). 16 A subset of DMs were previously found to be associated with loss of NF1 locus. 17 Recently, a patient with neurofibromatosis type 1 was found to have developed a DM. 18 As NF1 mutations are commonly found in peripheral nerve sheath tumors, 19, 20 and given the morphologic overlap of such tumors with DM, we reasoned that NF1 mutations may also be associated with DM and, therefore, examined DMs for their mutation status and compared them with a control set of primary and metastatic melanomas without desmoplasia.
MATERIALS AND METHODS

Patients
The study was approved by the institution's Institutional Review Board. Fifteen primary DMs and 20 non-DMs (2 primary, 18 metastatic tumor samples) were randomly selected. Of the 15 DMs, 7 tumors were pure DM characterized by a paucicellular fibrosing malignant spindle cell proliferation. Eight tumors were combined or mixed DM with both a classic paucicellular and a solid spindle cell tumor component ( Table 1) . One of the tumors was previously published as a case report. 16 non-DMs included 10 superficial spreading melanomas, 5 nodular, 3 acral, and 2 lentigo maligna melanomas.
Immunohistochemical Analysis
Sections of 5 mm thickness were taken from formalin-fixed, paraffin-embedded tissue and stained with an automated immunohistochemistry system according to the manufacturer's guidelines (Ventana BenchMark XT, Tucson, AZ) using a standard avidin-biotin procedure and antibodies for S100 protein and SOX10.
DNA Extraction and Targeted Sequencing
To enrich for the tumor cell population, nontumor tissue was manually removed from formalin-fixed, paraffin-embedded tissue sections, and areas with at least 50% neoplastic cells were scraped into sterile Eppendorf tubes. DNA was extracted with a QIAamp DNA FFPE Tissue Kit (Qiagen) according to the manufacturer's instructions. The extracted DNA was subjected to deepcoverage targeted sequencing using an assay termed MSK-IMPACT (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets).
The MSK-IMPACT assay uses target-specific oligonucleotides (NimbleGen SeqCap) to capture all proteincoding exons and selected introns of 341 cancer-associated genes (oncogenes, tumor-suppressor genes, and components of pathways deemed actionable by targeted therapies) and has been previously described. 21 Briefly, 250 ng genomic tumor DNA and a negative control pool of 10 "normal" blood DNAs was fragmented (Covaris E220) and used to prepare barcoded sequencing libraries (New England Biolabs, Kapa Biosystems). The sequencing libraries were pooled at equimolar concentrations (100 ng per library) and used in the capture reaction (NimbleGen SeqCap). To prevent off-target hybridization, we spiked in a pool of blocker oligonucleotides complementary to the full sequences of all barcoded adaptors. The captured libraries were sequenced on an Illumina HiSeq 2500 to generate 75 bp paired-end reads producing an average coverage of >500 per tumor.
Sequence data were demultiplexed using CASAVA and aligned to hg19 using BWA. 22 Local realignment and quality score recalibration were performed using the Genome Analysis Toolkit (GATK) according to GATK best practices. 23 Sequence data were analyzed to identify single-nucleotide variants and small insertions/deletions (indels) using MuTect 24 and GATK, respectively. Singlenucleotide variants and indels were called if the variant allele frequency in the tumor was present in >5% of sequencing reads and if the variant allele in the tumor was >5 times higher than in the negative control. We excluded variant alleles if they were present in >2% of reads in the negative control and if they were previously reported in dpSNP 25 or the 1000 genome project. 26 Single-nucleotide variants and indels were reviewed manually using the Integrative Genomics Viewer. 27 Oncoprints and MutationMaps were generated in the cBio portal. 28 
RESULTS
Clinical Characteristics
Fifteen primary cutaneous DMs were analyzed. The clinical and pathologic findings are summarized in Table 1 . The ages of the patients ranged from 24 to 85 years (mean = 65.7 y, median = 67 y). They included 10 men and 5 women. Thirteen tumors occurred in sundamaged skin of elderly individuals (Fig. 1 ). Two tumors occurred in skin without evidence of sun-damage in young adults. Ten tumors were located in the head and neck region, 3 on the upper trunk, and 2 on the upper extremities.
Pathologic and Immunohistochemical Features
Histopathologically, 12 of the 15 DMs had associated melanoma in situ ( Fig. 1 ). Tumor thickness ranged from 1.5 to 25 mm (mean = 9.6 mm, median = 9.5 mm). None of the tumors was ulcerated. Four invasive tumors were confined to the dermis. Eleven tumors extended into the subcutis (Clark V).
The DMs were strongly positive for S100 protein and SOX10 but negative for melan-A in the invasive tumor component. Melan-A was expressed by intraepidermal and intrafollicular melanoma cells (melanoma in situ).
Molecular Findings
Shared mutations, which were present in at least 30% of tumors, are shown in Figure 2 . The gene most commonly mutated in DM was NF1. Mutations of NF1 were detected in 14 of 15 (93%) primary cutaneous DMs. The vast majority of mutations in NF1 were nonsense, frameshift, or splice-site mutations that usually result in truncated nonfunctional proteins (Fig. 3 ). Genes mutated in at least 50% of the tumors included protein tyrosine phosphatase, receptor type T (PTPRT), protein tyrosine phosphatase, receptor type D (PTPRD), tumor protein p53 (TP53), and Ros protooncogene 1 (ROS1).
Mutations in BRAF, GNAQ, GNA11, and KIT were not identified in our cohort of DM. Only 1 tumor (case #7) had an NRAS mutation. Interestingly, this tumor harbored 2 missense mutations in NF1, whereas most other DMs contained at least 1 deleterious NF1 mutation (splice-site, nonsense, or frameshift mutations).
NF1 Mutations in Non-DM
To assess the frequency of NF1 mutations in nondesmoplastic cutaneous melanomas, we analyzed 20 tumors (18 metastases from known nondesmoplastic primaries, 2 primary melanomas). The tumors included 10 superficial spreading melanomas, 5 nodular melanomas, 3 acral melanomas, and 2 lentigo maligna melanomas. NF1 mutations were detected in 4 tumors (1 lentigo maligna melanoma and 3 nodular melanomas) ( Table 2 ). Three of the 4 non-DMs with NF1 mutations originated from the skin of the head and neck region; 1 tumor was from the skin of the back. In all non-DMs of this series, NF1 was associated with another mutation of the RAS/ RAF family: 2 cases had NRAS and another 2 had BRAF mutations.
DISCUSSION
We had previously noted inactivating mutations of NF1 in a combined tumor of desmoplastic and dedifferentiated sarcomatoid melanoma. 16 We now report that NF1 mutations are not unique to that case but occur at a high frequency in DM: NF1 mutations were found in 14 of 15 (93%) DMs.
In our control group of 20 cutaneous melanomas without desmoplasia, NF1 mutations were detected in 4 (20%) cases. Prior studies on the mutation profile of melanomas reported a frequency of NF1 mutations in 16 of 121 (13%) tumors 29 and in 13 of 91 (14%), 30 respectively. In a recent review, the overall frequency of NF1 mutations was estimated at 14% of cutaneous melanomas, with a total of 475 specimens analyzed. 31 No information was provided about the histopathologic subtype, but it is unlikely that a significant number of DMs was included in those studies, because DM is a rare variant of melanoma (approximately 4% of primary melanomas). 3, 32 Thus, compared with those reports and our control group of non-DMs, NF1 mutations are more commonly found in DM. NF1 encodes neurofibromin 1, a negative regulator of the Ras/mitogen-activated protein kinase (MAPK) pathway, a key pathway in melanomagenesis. 31 NF1 is a Ras-specific GTPase-activating protein that accelerates the hydrolysis of the active GTP-bound form of Ras into its inactive GDP-bound form, 33 but this is not the only mechanism by which NF1 can downregulate Ras. 31 Somatic mutations in NF1 have been observed in a variety of cancers, including melanoma. 31 Loss of NF1 detected in melanoma was reported in cell lines in the early 1990s, 34, 35 and 1 study reported loss of the NF1 locus in a subset of DMs. 17 Recently, loss of NF1 was shown to prevent BRAF oncogene-induced senescence in melanoma. 36 In addition, one of the mechanisms of resistance for RAF inhibitors is thought to occur through loss of NF1 expression. 37 NF1 mutations and loss of NF1 protein expression are known to occur in >90% of neurofibromatosis 1associated and in >40% of sporadic malignant peripheral nerve sheath tumors (MPNSTs). 19, 20, 38 MPNST and DM may show considerable morphologic and immunohistochemical overlap. The tumors reported herein are unequivocal melanomas and not MPNSTs, as all but 3 DMs of this series were associated with melanoma in situ, and the invasive component of all tumors was centered in the dermis and showed strong and diffuse labeling for S100 protein and SOX10. In addition, none of our patients had a history or clinical signs of neurofibromatosis.
A number of additional genes were commonly mutated in the DM of this series (Fig. 2) . These are genes known to be mutated in melanoma, but compared with their reported frequency in prior studies 29, 30 they seem to be more common in DM. TP53 mutations, for example, were detected in 19% of melanomas by Hodis et al 29 and in 12% of tumors by Krauthammer et al. 30 In our series of DM, TP53 was mutated in 60% of cases (Fig. 2) , and, interestingly, the majority of TP53 alterations were missense mutations that had clustered in the DNA binding domain.
Other highly mutated genes included the PTPRT (67%) and PTPRD (60%), which are known as tumorsuppressor genes and recognized for their regulatory function on numerous cellular processes including cell growth, cell fate, and cell cycle. Although the high frequency of mutations in these genes compared with prior sequencing studies of unselected melanoma (Hodis et al 29 : PTPRT: 26%, PTPRD: 17%; Krauthammer et al 30 : PTPRT: 0%, PTPRD: 24%) suggests some oncogenic impact in DM, thorough functional studies will be necessary to prove their pathogenetic relevance for several reasons. First, melanoma in general has a high background mutation rate, and it is difficult to distinguish pathogenetic relevant driver mutations from irrelevant passenger mutations. Previous studies reported very high point mutation rates in patients with a history of chronic sun exposure, and given the association of DM with chronic UV exposure, 39 high mutation rates in DM should come as no surprise. Second, whereas most mutations in NF1 were deleterious (nonsense, frameshift, or splice-site mutations), the mutation pattern found in the other genes was mainly composed of missense mutations. Missense mutations usually result in the exchange of 1 amino acid and thus may have only minor effects on the protein function. Third, the missense mutations were quite randomly distributed across the genes, and no hotspot mutations were found. Consequently, the impact of missense mutations on the protein function is unclear, and functional studies are necessary to analyze their oncogenic consequences.
In summary, having used targeted next-generation sequencing for 341 cancer-related genes, we document that inactivating NF1 mutations are more common in DMs than in non-DMs. The finding provides further evidence that DM is, at the molecular level, distinct from conventional melanoma. The fact that NF1 mutations are commonly seen in both pure and mixed DM suggests that they occur early in the evolution of DM and do not merely reflect tumor progression. This is further supported by the fact that NF1 mutations can be found in a lentigo maligna melanoma in situ (K.J.B., unpublished observation, 2014). It is possible that mutations in genes that are not covered by our sequencing assay may also be associated with and play an important role in DM. However, given the high frequency of NF1 mutations in our series of tumors, we believe that NF1 is relevant for the biology of DM and for discussions of targeted treatment of recurrences thereof.
